Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

被引：8
|
作者：
Zinzani, Pier Luigi [1 ]
Topp, Max S. [2 ]
Yuen, Sam L. S. [3 ]
Rusconi, Chiara [4 ]
Fleury, Isabelle [5 ,6 ]
Pro, Barbara [7 ]
Gritti, Giuseppe [8 ]
Crump, Michael [9 ]
Hsu, Wanling [10 ]
Punnoose, Elizabeth A. [10 ]
Hilger, James [10 ]
Mobasher, Mehrdad [10 ]
Hiddermann, Wolfgang [11 ]
机构：
[1] Univ Bologna, Inst Hematol LEA Seragnoli, Bologna, Italy
[2] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[3] Calvary Mater Newcastle, Dept Haematol, Newcastle, NSW, Australia
[4] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy
[5] Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Osped Papa Giovanni XXIII, Hematol & BMT Unit, Bergamo, Italy
[9] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[10] Genentech Inc, San Francisco, CA USA
[11] Klinikum Univ Munchen, Dept Internal Med 3, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.617.617
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
617
引用
收藏
页数：7
相关论文
共 50 条
  • [41] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
  • [42] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
    Falchi, Lorenzo
    Abrisqueta, Pau
    Nijland, Marcel
    Leppa, Sirpa
    Hutchings, Martin
    Holte, Harald
    Merryman, Reid W.
    Lugtenburg, Pieternella
    de Vos, Sven
    Cheah, Chan Y.
    Christensen, Jacob Haaber
    Arcaini, Luca
    Drott, Kristina
    Hellstrom, Mats
    Leslie, Lori A.
    Vitolo, Umberto
    Rana, Ali
    Abbas, Aqeel
    Wang, Liwei
    Minh Dinh
    Belada, David
    BLOOD, 2022, 140 : 1464 - 1466
  • [43] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
  • [45] Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
    Batlevi, Connie Lee
    Park, Steven I.
    Nastoupil, Loretta
    Phillips, Tycel
    Amengual, Jennifer E.
    Andorsky, David
    Campbell, Philip
    McKay, Pamela
    Pagel, John M.
    Leonard, John P.
    Yang, Jay
    O'Connor, Heather
    Hamlett, Anthony
    Adib, Deyaa
    Morschhauser, Franck
    BLOOD, 2021, 138
  • [46] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [47] Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Coiffier, Bertrand
    Osmanov, Evgenii A.
    Hong, Xiaonan
    Scheliga, Adriana
    Mayer, Jiri
    Offner, Fritz
    Rule, Simon
    Teixeira, Adriana
    Walewski, Jan
    de Vos, Sven
    Crump, Michael
    Shpilberg, Ofer
    Esseltine, Dixie-Lee
    Zhu, Eugene
    Enny, Christopher
    Theocharous, Panteli
    van de Velde, Helgi
    Elsayed, Yusri A.
    Zinzani, Pier Luigi
    LANCET ONCOLOGY, 2011, 12 (08): : 773 - 784
  • [48] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
    Sehn, Laurie H.
    Luminari, Stefano
    Scholz, Christian W.
    Huebel, Kai
    Salar, Antonio
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Panayiotidis, Panayiotis
    Lee, Hui-Peng
    Ubieto, Ana Jimenez
    Sancho, Juan-Manuel
    Kim, Tae Min
    Domenech, Eva Domingo
    Kumode, Takahiro
    Poh, Christina
    Thieblemont, Catherine
    Deeren, Dries
    de Wit, Edwin
    Arbushites, Michael
    Casadebaig, Marie-Laure
    Trneny, Marek
    BLOOD, 2024, 144 : LBA1 - LBA4
  • [49] Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance
    D'Alo, Francesco
    Malafronte, Rosalia
    Piludu, Francesca
    Bellesi, Silvia
    Cuccaro, Annarosa
    Maiolo, Elena
    Modoni, Anna
    Leccisotti, Lucia
    Macis, Giuseppe
    Mores, Nadia
    De Stefano, Valerio
    Hohaus, Stefan
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : E138 - E142
  • [50] A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis
    Zheng, Zhong
    Wang, Li
    Cheng, Shu
    Xu, Pengpeng
    Zhao, Weili
    BLOOD, 2019, 134
12345